2022
Safety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complications
2017
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies
Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular side effectsHematologic malignanciesSide effectsUnique side effect profileCardiovascular adverse eventsSide effect profileLong-term administrationNon-Hodgkin lymphomaChronic myeloid leukemiaTyrosine kinase inhibitorsYears of ageOrgan-specific toxicityAdverse eventsFace of treatmentTargeted agentsEffect profilePatient populationCardiovascular toxicityMyeloid leukemiaNew agentsPreemptive managementMalignancyPrior exposureKinase inhibitorsProteasome inhibitors